

Weekly COVID-19 Update in Montana (as of 5/14/2021)

This report is a weekly snapshot of COVID-19 activity in Montana. Data is analyzed based on information available as of May 14, 2021. Data is provisional and expected to change as more information is received.

Case Data

Table 1. Summary of COVID-19 Activity – Montana, as of 5/14/2021

			PERCENT CHANGE FROM
	TOTAL	RECENT WEEK	PREVIOUS WEEK
REPORTED CASES	110,644	759	-16%
LABORATORY TESTS	1,342,000	17,705	-20%
HOSPITALIZATIONS	5,154	67	+4%
DEATHS	1,598	4	+50%

Figure 1. COVID-19 Cases and Hospitalizations over Time - Montana, as of 5/14/2021





Figure 2. COVID-19 Deaths by Report Date and Date of Death - Montana, 11/1/2020 - 5/14/2021





Vaccine Data – updated through 5/17/2021

Montana began vaccinating individuals in mid-December 2020 with a phased process: Phase 1A on December 14, 2020, Phase 1B on January 19, 2021, and Phase 1B+ on March 8, 2021. Vaccinations were opened to all Montanans age 16+ on April 1, 2021 and expanded to all Montanans age 12+ on May 10th, 2021. To date 771,505 doses have been given across the state and 40% of the eligible population are considered fully vaccinated. This week, Montana's vaccine allocation was 28,080 first doses and 28,080 second doses.

COVID-19 Vaccine Doses Administered – Montana, as of 5/17/2021

	TOTAL	RECENT WEEK	PERCENT CHANGE FROM
			PREVIOUS WEEK
TOTAL DOSES ADMINISTERED	771,705	24,058	-30%
FULLY VACCINATED	353,190	16,315	-38%

Figure 3. COVID-19 Vaccine Doses Administered by Week – Montana, as of 5/17/2021





Figure 4. Percent of Eligible Montanans (12+ years) Fully Vaccinated by County – Montana, 5/17/2021





Variant and Breakthrough Cases

A variant has one or more mutations that differentiate it from other viral strains in circulation. Multiple variants of SARS-COV-2 have been documented throughout this pandemic. To date, 216 variants of concern have been identified in Montana. The most common variant identified (53% of specimens) is B.1.1.7 (UK strain).

A breakthrough COVID-19 infection is defined as a positive SARS-CoV-2 collected ≥14 days after completing the primary COVID-19 vaccine series of an FDA-authorized COVID-19 vaccine. Depending on the specific vaccine administered, completion of series could be one or two doses of vaccine. As of 5/14/2021, 159 cases of confirmed breakthrough disease were reported, including 16 hospitalizations and two deaths.